Q3 2016 EPS Estimates for Cipher Pharmaceuticals Inc Cut by Cormark (CPH)

Cipher Pharmaceuticals Inc (TSE:CPH) – Analysts at Cormark decreased their Q3 2016 earnings estimates for Cipher Pharmaceuticals in a research note issued to investors on Monday. Cormark analyst D. Novak now forecasts that the brokerage will earn ($0.13) per share for the quarter, down from their previous estimate of ($0.07). Cormark also issued estimates for Cipher Pharmaceuticals’ Q4 2016 earnings at ($0.08) EPS, FY2016 earnings at ($0.51) EPS and Q4 2017 earnings at $0.04 EPS.

Earnings History and Estimates for Cipher Pharmaceuticals (TSE:CPH)

Several other research analysts have also recently weighed in on the stock. TD Securities reiterated a “buy” rating and issued a C$7.50 price target on shares of Cipher Pharmaceuticals in a report on Thursday, August 11th. GMP Securities cut shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 11th.

Cipher Pharmaceuticals (TSE:CPH) opened at 4.99 on Wednesday. The company has a 50-day moving average of $5.24 and a 200 day moving average of $6.59. The company’s market cap is $130.71 million. Cipher Pharmaceuticals has a one year low of $4.81 and a one year high of $8.18.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.

Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.